Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation

Aurobindo Pharma

Status and phase: Withdrawn; Phase 3

Conditions: Bronchial Asthma

Treatments: Drug: Albuterol Sulfate HFA 0.18 mg (Test); Drug: Albuterol Sulfate HFA 0.18 mg (Reference); Drug: Albuterol Sulfate HFA 0.09 mg (Reference); Drug: Placebo; Other: Methacholine Chloride; Drug: Albuterol Sulfate HFA 0.09 mg (Test)

Study type: Interventional

Funder types: Industry

Identifiers

NCT05292976

CR206-19

Details and patient eligibility

About

Pharmacodynamic bioequivalence study of Albuterol Sulfate Inhalation Aerosol 0.09 mg

Full description

To assess the pharmacodynamic bioequivalence of Albuterol Sulfate Inhalation Aerosol 0.09 mg base/ INH [Aurobindo Pharma, USA, Inc] compared to authorized generic drug Albuterol Sulfate HFA Inhalation Aerosol 0.09 mg per actuation [Teva Pharmaceuticals USA, Inc] in stable mild asthma patients, under Methacholine induced bronchoprovocation.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male and non-pregnant female subjects (18-65 years of age).
2. Stable mild asthmatics based on National Asthma Education and Prevention Program (NAEPP) guidelines.
3. FEV1 ≥ 80% of predicted.
4. Airway responsiveness to methacholine demonstrated by a pre-albuterol dose (baseline) PC20 ≤ 8 mg/mL or equivalent PD20.
5. Nonsmokers for at least six months prior to the study and a maximum smoking history of five pack-years (the equivalent of one pack per day for five years).
6. Written informed consent.

Exclusion criteria

1. Evidence of upper or lower respiratory tract infection (e.g., pneumonia, bronchitis, sinusitis) within six weeks prior to the study.
2. History of seasonal asthma exacerbations, in which case the subject should be studied outside of the relevant allergen season.
3. History of cystic fibrosis, bronchiectasis or other respiratory diseases.
4. History of cardiovascular, renal, neurologic, liver or endocrine dysfunction, including ECG with evidence of ischemic heart disease.
5. Treatment in an emergency room or hospitalization for acute asthmatic symptoms or need for daily oral corticosteroids within past three months.
6. Known intolerance or hypersensitivity to any component of the albuterol MDI

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

0 participants in 5 patient groups, including a placebo group

Zero dose:

Placebo Comparator group

Treatment:

Drug: Placebo

Other: Methacholine Chloride

Reference 0.09 mg

Active Comparator group

Treatment:

Drug: Albuterol Sulfate HFA 0.09 mg (Reference)

Other: Methacholine Chloride

Reference 0.18 mg

Active Comparator group

Treatment:

Drug: Albuterol Sulfate HFA 0.18 mg (Reference)

Other: Methacholine Chloride

Test 0.09 mg

Experimental group

Treatment:

Drug: Albuterol Sulfate HFA 0.09 mg (Test)

Other: Methacholine Chloride

Test 0.18 mg

Experimental group

Treatment:

Drug: Albuterol Sulfate HFA 0.18 mg (Test)

Other: Methacholine Chloride